20-F: Alvotech's 2023 Financial Results: Revenue Growth Offset by Increased Operating Losses

Alvotech's 2023 financial results show increased product revenue but also significant operating losses, highlighting the challenges of biosimilar development and commercialization.

Summary

• Alvotech's 2023 financial results show increased product revenue but also significant operating losses.
• The company's loss for the year ended December 31, 2023, was $551.7 million, compared to $513.6 million in 2022 and $101.5 million in 2021.
• Product revenue increased to $48.7 million in 2023 from $24.8 million in 2022, driven by the launch of AVT02 in select markets.
• License and other revenue decreased to $42.7 million in 2023 from $58.2 million in 2022, mainly due to the timing of milestone payments.
• Research and development expenses increased to $210.8 million in 2023 from $180.6 million in 2022, reflecting ongoing clinical development activities.
• General and administrative expenses decreased to $76.6 million in 2023 from $186.7 million in 2022, primarily due to non-recurring expenses related to the Business Combination in 2022.
• The company has identified material weaknesses in its internal control over financial reporting.
• As of December 31, 2023, Alvotech had $11.2 million in cash and cash equivalents, excluding restricted cash.
• In February 2024, Alvotech accepted an offer for the sale of 10,127,132 Ordinary Shares for gross proceeds of approximately $166 million.
• There is a material uncertainty that may cast significant doubt about Alvotech's ability to continue as a going concern.

Sentiment

Score: 4

Explanation: The document presents a mixed picture, with positive developments such as product launches and regulatory approvals, but also significant financial challenges and material weaknesses in internal controls.

Positives

• Product revenue nearly doubled in 2023, reaching $48.7 million, driven by AVT02 sales.
• The company completed a private placement in February 2024, raising approximately $166 million.
• The company received U.S. FDA approval for AVT02 as an interchangeable high-concentration citrate-free biosimilar to Humira in February 2024.
• The company launched AVT04 in Canada in March 2024 and expects launches in Japan and Europe in Q2 and Q3 2024, respectively.

Negatives

• The company's operating loss increased to $551.7 million in 2023.
• License and other revenue decreased to $42.7 million in 2023 from $58.2 million in 2022, mainly due to the timing of milestone payments.
• The company has identified material weaknesses in its internal control over financial reporting.
• As of December 31, 2023, Alvotech had $11.2 million in cash and cash equivalents, excluding restricted cash.
• There is a material uncertainty that may cast significant doubt about Alvotech's ability to continue as a going concern.

Risks

• The company has a limited operating history and has incurred significant losses since inception.
• The company has substantial indebtedness and may need to raise additional funding.
• The regulatory approval processes are lengthy and time-consuming.
• The company relies on third parties for clinical studies and manufacturing.
• The company faces significant competition from reference products and other biosimilars.
• The company is dependent on partners for commercialization in certain markets.
• The company may infringe on the intellectual property rights of third parties.
• The company has identified material weaknesses in its internal control over financial reporting.
• Future issuances of debt and equity securities may adversely affect the company.

Future Outlook

Alvotech expects to launch AVT02 in the United States during the first half of 2024 and AVT04 in Japan and Europe in Q2 and Q3 2024, respectively.

Industry Context

The announcement reflects the ongoing dynamics in the biosimilar industry, with companies like Alvotech striving to gain market share amid competition from both reference product manufacturers and other biosimilar developers.

Comparison to Industry Standards

• Alvotech's financial performance can be compared to other biosimilar companies such as Amgen, Celltrion, and Sandoz, considering their revenue growth, R&D spending, and profitability.
• The success of AVT02 and AVT04 launches will be crucial in determining Alvotech's ability to compete with established players in the biosimilar market.
• The company's ability to secure interchangeability designation for AVT02 in the U.S. provides a competitive advantage compared to other biosimilars that do not have this designation.
• The company's reliance on partnerships for commercialization is a common strategy in the biosimilar industry, but it also carries risks related to partner performance.

Corporate Governance

Legal Proceedings

• The company was in legal proceedings adverse to AbbVie, and its Canadian partner JAMP continues to be, relating to AVT02.

Related Party Transactions

• The company has entered into various service agreements with its direct and indirect significant shareholders and related entities, such as Alvogen, Aztiq, Alvogen Malta (Out-Licensing) Ltd. (Adalvo) and Floki Invest ehf. for IT services, corporate administrative, legal, financial, facility management, portfolio and market intelligence research, regulatory compliance, quality audit, and publishing services, and certain administrative and financial services related to our Reykjavik facility.

Stakeholder Impact

• The company's financial challenges and material weaknesses in internal controls may negatively impact investor confidence.
• The company's efforts to launch biosimilars and expand access to affordable medicines may benefit patients and healthcare systems.
• The company's reliance on partnerships may impact the commercial success of its products and the returns for its shareholders.

Next Steps

• Launch AVT02 in the United States during the first half of 2024.
• Launch AVT04 in Japan and Europe in Q2 and Q3 2024, respectively.
• Complete the FDA review of the BLA for AVT04 by 16 April 2024.
• Continue clinical development of AVT03, AVT05, AVT06, and AVT23.
• Address the material weaknesses in internal control over financial reporting.

Key Dates

Keywords

Alvotech, biosimilars, financial results, revenue, operating loss, AVT02, AVT04, clinical trials, regulatory approval, Humira, Stelara, debt, capital raise, material weakness, going concern